# Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease

Study · id `cardio:ct-nct01422421` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01422421](<https://clinicaltrials.gov/study/NCT01422421>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01422421

Browse, organ or system: Heart; Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 798 participants.

## Technical summary

Registry record NCT01422421. Randomized; double masking; primary purpose prevention. Start 2011-08 (registry gives no type); primary completion 2022-03-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 798 participants (enrolled count; ClinicalTrials.gov record NCT01422421, source copy `cardio:ctgov-nct01422421-2024-06-14`, retrieved 2026-10-26)
- Start date: 2011-08 (registry gives no type) (ClinicalTrials.gov record NCT01422421, source copy `cardio:ctgov-nct01422421-2024-06-14`, retrieved 2026-10-26)
- Primary completion: 2022-03-31 (actual) (ClinicalTrials.gov record NCT01422421, source copy `cardio:ctgov-nct01422421-2024-06-14`, retrieved 2026-10-26)
- Completion: 2023-12-31 (actual) (ClinicalTrials.gov record NCT01422421, source copy `cardio:ctgov-nct01422421-2024-06-14`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01422421, source copy `cardio:ctgov-nct01422421-2024-06-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01422421-2024-06-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease
- Condition: Type 2 Diabetes
- Condition: Coronary Artery Disease
- Condition: Hypertension
- Condition: Dyslipidemia
- Intervention (Other): intensive control
- Intervention (Other): standard control
- Lead sponsor: Takeshi Morimoto
- Lead sponsor class: OTHER
- Collaborator: University of the Ryukyus
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Takeshi Morimoto (`cardio:org-takeshi-morimoto`)

## Provenance

Content hash: 00a1497904e8104676c524def988af77a992312fa4cd482e2afebf46eb9c901c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
